A randomized pilot study to evaluate graft versus fistula vascular access strategy in older patients with advanced kidney disease: results of a feasibility study.
Arteriovenous vascular access
Hemodialysis
Kidney disease
Older adults
Randomized trial
Journal
Pilot and feasibility studies
ISSN: 2055-5784
Titre abrégé: Pilot Feasibility Stud
Pays: England
ID NLM: 101676536
Informations de publication
Date de publication:
2020
2020
Historique:
received:
27
01
2020
accepted:
24
05
2020
entrez:
20
6
2020
pubmed:
20
6
2020
medline:
20
6
2020
Statut:
epublish
Résumé
Although older adults encompass almost half of patients with advanced chronic kidney disease, it remains unclear which long-term hemodialysis vascular access type, arteriovenous fistula or arteriovenous graft, is optimal with respect to effectiveness and patient satisfaction. Clinical outcomes based on the initial AV access type have not been evaluated in randomized controlled trials. This pilot study tested the feasibility of randomizing older adults with advanced kidney disease to initial arteriovenous fistula versus graft vascular access surgery. Patients 65 years or older with pre-dialysis chronic kidney disease or incident end-stage kidney disease and no prior arteriovenous vascular access intervention were randomized in a 1:1 ratio to undergo surgical placement of a fistula or a graft after providing informed consent. Trial feasibility was evaluated as (i) recruitment of ≥ 70% of eligible participants, (ii) ≥ 50 to 70% of participants undergo placement of index arteriovenous access within 90 to 180 days of enrollment, respectively, (iii) ≥ 80% adherence to study-related assessments, and (iv) ≥ 70% of participants who underwent index arteriovenous access placement will have a follow-up duration of ≥ 12 months after index surgery date. Between September 2018 and October 2019, 81% (44/54) of eligible participants consented and were enrolled in the study; 11 had pre-dialysis chronic kidney disease, and 33 had incident or prevalent end-stage kidney disease. After randomization, 100% (21/21) assigned to arteriovenous fistula surgery and 78% (18/23) assigned to arteriovenous graft surgery underwent index arteriovenous access placement within a median (1st, 3rd quartile) of 5.0 (1.0, 14.0) days and 13.0 (5.0, 44.3) days, respectively, after referral to vascular surgery. The completion rates for study-specific assessments ranged between 40.0 and 88.6%. At median follow-up of 215.0 days, 5 participants expired, 7 completed 12 months of follow-up, and 29 are actively being followed. Assessments of grip strength, functional independence, and vascular access satisfaction were completed by > 85% of patients who reached pre-specified post-operative assessment time point. Results from this study reveal it is feasible to enroll and randomize older adults with advanced kidney disease to one of two different arteriovenous vascular access placement surgeries. The study can progress with minor protocol adjustments to a multisite clinical trial. Clinical Trials ID, NCT03545113.
Sections du résumé
BACKGROUND
BACKGROUND
Although older adults encompass almost half of patients with advanced chronic kidney disease, it remains unclear which long-term hemodialysis vascular access type, arteriovenous fistula or arteriovenous graft, is optimal with respect to effectiveness and patient satisfaction. Clinical outcomes based on the initial AV access type have not been evaluated in randomized controlled trials. This pilot study tested the feasibility of randomizing older adults with advanced kidney disease to initial arteriovenous fistula versus graft vascular access surgery.
METHODS
METHODS
Patients 65 years or older with pre-dialysis chronic kidney disease or incident end-stage kidney disease and no prior arteriovenous vascular access intervention were randomized in a 1:1 ratio to undergo surgical placement of a fistula or a graft after providing informed consent. Trial feasibility was evaluated as (i) recruitment of ≥ 70% of eligible participants, (ii) ≥ 50 to 70% of participants undergo placement of index arteriovenous access within 90 to 180 days of enrollment, respectively, (iii) ≥ 80% adherence to study-related assessments, and (iv) ≥ 70% of participants who underwent index arteriovenous access placement will have a follow-up duration of ≥ 12 months after index surgery date.
RESULTS
RESULTS
Between September 2018 and October 2019, 81% (44/54) of eligible participants consented and were enrolled in the study; 11 had pre-dialysis chronic kidney disease, and 33 had incident or prevalent end-stage kidney disease. After randomization, 100% (21/21) assigned to arteriovenous fistula surgery and 78% (18/23) assigned to arteriovenous graft surgery underwent index arteriovenous access placement within a median (1st, 3rd quartile) of 5.0 (1.0, 14.0) days and 13.0 (5.0, 44.3) days, respectively, after referral to vascular surgery. The completion rates for study-specific assessments ranged between 40.0 and 88.6%. At median follow-up of 215.0 days, 5 participants expired, 7 completed 12 months of follow-up, and 29 are actively being followed. Assessments of grip strength, functional independence, and vascular access satisfaction were completed by > 85% of patients who reached pre-specified post-operative assessment time point.
CONCLUSIONS
CONCLUSIONS
Results from this study reveal it is feasible to enroll and randomize older adults with advanced kidney disease to one of two different arteriovenous vascular access placement surgeries. The study can progress with minor protocol adjustments to a multisite clinical trial.
TRIAL REGISTRATION
BACKGROUND
Clinical Trials ID, NCT03545113.
Identifiants
pubmed: 32551134
doi: 10.1186/s40814-020-00619-9
pii: 619
pmc: PMC7298797
doi:
Banques de données
ClinicalTrials.gov
['NCT03545113']
Types de publication
Journal Article
Langues
eng
Pagination
86Subventions
Organisme : NIA NIH HHS
ID : R03 AG060178
Pays : United States
Informations de copyright
© The Author(s) 2020.
Déclaration de conflit d'intérêts
Competing interestsThe authors declare that they have no competing interests.
Références
J Vasc Access. 2009 Jul-Sep;10(3):199-202
pubmed: 19670174
Clin J Am Soc Nephrol. 2017 Jun 7;12(6):947-954
pubmed: 28522655
JAMA. 1963 Sep 21;185:914-9
pubmed: 14044222
Kidney Int. 2010 Jan;77(2):141-51
pubmed: 19907414
PLoS One. 2013 Aug 06;8(8):e68748
pubmed: 23936310
J Am Soc Nephrol. 2006 Nov;17(11):3204-12
pubmed: 16988062
Clin Geriatr Med. 2001 Aug;17(3):457-78, vi
pubmed: 11459715
Clin J Am Soc Nephrol. 2013 May;8(5):810-8
pubmed: 23371955
J Am Soc Nephrol. 2017 Feb;28(2):645-652
pubmed: 27605542
BMJ. 2011 Oct 18;343:d5928
pubmed: 22008217
Kidney Int. 2002 Aug;62(2):620-6
pubmed: 12110026
BMC Med Res Methodol. 2011 Aug 16;11:117
pubmed: 21846349
Clin J Am Soc Nephrol. 2007 Sep;2(5):1043-53
pubmed: 17702726
Nephrol Dial Transplant. 2014 May;29(5):990-6
pubmed: 23787545
J Vasc Surg. 2007 Feb;45(2):420-426
pubmed: 17264030
Ann Intern Med. 2007 Feb 6;146(3):177-83
pubmed: 17283348
Qual Life Res. 1994 Oct;3(5):329-38
pubmed: 7841967
Gerontologist. 1969 Autumn;9(3):179-86
pubmed: 5349366
Kidney Int. 2005 Jul;68(1):311-8
pubmed: 15954922
BMC Med Res Methodol. 2010 Jan 06;10:1
pubmed: 20053272
Semin Dial. 2002 Mar-Apr;15(2):116-20
pubmed: 11952939
Cardiovasc Eng Technol. 2017 Sep;8(3):244-254
pubmed: 28695442
J Gerontol A Biol Sci Med Sci. 2014 May;69(5):547-58
pubmed: 24737557
Clin J Am Soc Nephrol. 2011 Jul;6(7):1651-62
pubmed: 21734085
BMC Med Res Methodol. 2010 Jul 16;10:67
pubmed: 20637084
Contemp Clin Trials Commun. 2019 Apr 09;14:100357
pubmed: 31016270
Am J Kidney Dis. 2006 Jul;48 Suppl 1:S176-247
pubmed: 16813989
J Vasc Surg. 2018 May;67(5):1491-1500
pubmed: 29224945
Clin J Am Soc Nephrol. 2012 Jun;7(6):1039-46
pubmed: 22516288
J Vasc Surg. 2016 May;63(5):1326-32
pubmed: 26776449
PLoS Med. 2010 Mar 24;7(3):e1000251
pubmed: 20352064
Kidney Int. 2001 Oct;60(4):1443-51
pubmed: 11576358
Clin J Am Soc Nephrol. 2007 Jan;2(1):89-99
pubmed: 17699392
Am J Nephrol. 2019;49(1):11-19
pubmed: 30544112
Kidney Int. 2014 Jan;85(1):158-65
pubmed: 23802192
J Vasc Access. 2015 May-Jun;16(3):200-5
pubmed: 25634153